secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001193125-21-235830
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics appoints Yuan Xu, Ph.D. to Board of Directors
---------------------------------------------------------------

- Board expanded from 9 to 10 directors; Yuan Xu appointed as Class II director effective August 3, 2021.
- Dr. Xu granted option to purchase 7,501 shares and RSUs for 4,744 shares, vesting over 3 years.
- Dr. Xu previously CEO of Legend Biotech, led cilta-cel development and partnership with Janssen.
- Over 25 years biopharma experience including senior roles at Merck, Gilead, and Novartis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/0001193125-21-235830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/d213764d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-235830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer